University of Kentucky

UKnowledge
Markey Cancer Center Faculty Publications

Markey Cancer Center

11-6-2017

The Role of Talin2 in Breast Cancer Tumorigenesis and
Metastasis
Liqing Li
University of Kentucky, liqing.li@uky.edu

Xiang Li
University of Kentucky

Lei Qi
University of Kentucky, lei.qi@uky.edu

Piotr G. Rychahou
University of Kentucky, piotr.rychahou@uky.edu

Naser Jafari
University of Kentucky, naser.jafari@uky.edu

See next page for additional authors

Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub
Part of the Cancer Biology Commons, Cell Biology Commons, and the Oncology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Li, Liqing; Li, Xiang; Qi, Lei; Rychahou, Piotr G.; Jafari, Naser; and Huang, Cai, "The Role of Talin2 in Breast
Cancer Tumorigenesis and Metastasis" (2017). Markey Cancer Center Faculty Publications. 97.
https://uknowledge.uky.edu/markey_facpub/97

This Article is brought to you for free and open access by the Markey Cancer Center at UKnowledge. It has been
accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

The Role of Talin2 in Breast Cancer Tumorigenesis and Metastasis
Digital Object Identifier (DOI)
https://doi.org/10.18632/oncotarget.22449

Notes/Citation Information
Published in Oncotarget, v. 8, no. 63, p. 106876-106887.
Copyright: Li et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.

Authors
Liqing Li, Xiang Li, Lei Qi, Piotr G. Rychahou, Naser Jafari, and Cai Huang

This article is available at UKnowledge: https://uknowledge.uky.edu/markey_facpub/97

www.impactjournals.com/oncotarget/

Oncotarget, 2017, Vol. 8, (No. 63), pp: 106876-106887
Research Paper

The role of talin2 in breast cancer tumorigenesis and metastasis
Liqing Li1,*, Xiang Li1,*, Lei Qi1, Piotr Rychahou1, Naser Jafari1 and Cai Huang1,2
1

Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA

2

Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40506, USA

*

These authors contributed equally to this work

Correspondence to: Cai Huang, email: cai-huang@uky.edu
Keywords: talin2; cell migration; invasion; tumor growth; metastasis
Received: August 06, 2017     Accepted: October 25, 2017     Published: November 06, 2017
Copyright: Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT
Recent studies show that talin2 has a higher affinity to β-integrin tails and is
indispensable for traction force generation and cell invasion. However, its roles in
cell migration, cancer cell metastasis and tumorigenesis remain to be determined.
Here, we used MDA-MB-231 human breast cancer cells as a model to define the roles
of talin2 in cell migration, invasion, metastasis and tumorigenesis. We show here
that talin2 knockdown (KD) inhibited cell migration and focal adhesion dynamics,
a key step in cell migration, and that talin2 knockout (KO) inhibited cell invasion
and traction force generation, the latter is crucial for cell invasion. Re-expression of
talin2WT in talin2-KO cells restored traction force generation and cell invasion, but that
of talin2S339C, a β-integrin-binding deficient mutant, did not. Moreover, talin2 KO (or
KD) suppressed tumorigenesis and metastasis in mouse xenograft models. However,
surprisingly, re-expression of talin2WT in talin2-KO cells did not rescue tumorigenesis.
Thus, talin2 is required for breast cancer cell migration, invasion, metastasis and
tumorigenesis, although exogenous expression of high levels of talin2 could inhibit
tumorigenesis.

INTRODUCTION

stability and matrix degradation [19]. It is also required
for the generation of mechanical force [23], a driver of
cell migration and invasion. However, the role of talin2 in
these processes are less understood. It has been reported
that depletion of talin2 does not influence β1-integrin
activation [14], and that talin2-ablated mice are viable
[24]. Thus, it was originally thought that talin2 functioned
redundantly with talin1.
However, we demonstrated that talin2 had a stronger
binding to β integrin tails than talin1 [25, 26]. Talin2
Ser339 is largely responsible for this affinity difference
and substitution of Ser339 with Leu disrupted the binding
of talin2 to β1-integrin tails. We also demonstrated
that talin2 is localized at invadopodia and that a strong
talin2-integrins interaction is required for traction force
generation and invadopodium formation and cell invasion
[25].
In the present study, we used highly aggressive
breast cancer cell line MDA-MB-231 cells as a model to
investigate the role of talin2 in cell migration, invasion,
tumor growth and metastasis. We found that talin2 plays a

Integrin-mediated mechanic signals regulate tumor
cell migration, invasion, growth and metastasis [1–6].
Integrins are heterodimers, comprising of α (alpha) and β
(beta) subunits [7]. Talin, a large focal adhesion protein,
binds to the β subunits, thus activating integrin and
regulating a variety of physiological and pathological
processes [8–11].
There are two talin genes, Tln1 and Tln2, encoding
talin1 and talin2, respectively [12]. Talin1 is essential for
cell migration, invasion, tumor growth and metastasis
[13–16]. Talin1 regulates focal adhesion (FA) dynamics
[13, 17, 18] and invadopodium formation [19], key
steps in cell migration and invasion [20–22]. Talin1
also mediates calpain-induced FA disassembly [17,
18]. Along with our collaborators, we have shown that
talin1 phosphorylation by Cdk5 regulates FA dynamics,
integrin activation, cell migration and invasion [13, 14].
It recruits the moesin-NHE1 complex to modulate pH
at invadopodia, consequently governing invadopodium
www.impactjournals.com/oncotarget
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crucial role in cell migration, invasion, tumorigenesis and
metastasis, although exogenous expression of high levels
of talin2 could suppress tumorigenesis.

of the full-length talin2 to β-integrins. As shown in
Figure 2D, substitution of S339 with Cys also resulted in
significant reduction in the binding of the full-length talin2
to β1A-integrin tail.
To determine the essential role of the talin2-βintegrin interaction in cell invasion, EGFP-talin2WT and
-talin2S339C were re-expressed in talin2-null MDA-MB-231
cells, respectively (Figure 2E). The invasive capacities of
these cells toward Matrigel were tested, using talin2-null
cells and CRISPR vector cells as controls. Expression of
EGFP-talin2WT in talin2-null cells significantly rescued the
basal and HGF-stimulated cell invasion (Figure 2F, 2G).
Expression of EGFP-talin2S339C had no effect on basal
invasion, but partially rescued HGF-stimulated invasion
(P < 0.05 KO vs S339C), suggesting that a strong binding
of talin2 to integrins is required for cell invasion.
Because traction force plays an important role in
cell migration and invasion [23, 25, 28], we set out to
examine the role of talin2 in traction force generation.
To this end, talin2-null MDA-MB-231 cells were
plated on the fibronectin-conjugated polyacrylamide
gels containing Red Fluospheres (Life Technologies),
using cells carrying empty CRISPR vector as a control.
Traction force was measured by a Nikon A1 confocal
microscope equipped with a CO2 incubator system, and
was analyzed using the method of Butler et al. Ablation
of talin2 almost abolished the traction force generation in
MDA-MB-231 cells (Figure 3A, 3B). To know whether a
strong talin2-β-integrin interaction is required for traction
force generation, talin2-null MDA-MB-231 cells that
express EGFP-talin2WT or –talin2S339C were plated on the
gels containing Red FluoSpheres, and traction force was
measured using talin2-null cells and CRISPR vector cells
as controls. Expression of EGFP-talin2WT in talin2-null
MDA-MB-231 cells restored more than 85% of traction
force, whereas that of EGFP-talin2S339C, which has reduced
affinity to β-integrins, had little effect (Figure 3C, 3D).
This result suggests that a strong binding of talin2 to
β-integrins is required for traction force generation.
To study the role of talin2 in tumorigenesis, talin2null MDA-MB-231 cells were injected into female
NCRNU mice (Taconic) by subcutaneous injection, using
cells that were infected with empty LentiCrispr vector
as a control. Tumor volumes were measured at 3–7 day
intervals. As shown in Figure 4A, tumor volumes from
mice injected with talin2-null cells were significantly
smaller than those from mice injected with the cells
transfected with empty vector. At 36 days after injection,
mice were euthanized, and tumors were removed,
photographed and weighted. Talin2 KO significantly
inhibited tumor growth (Figure 4B, 4C). The role of
talin2 in tumorigenesis was further demonstrated by
using talin2 KD cells. To compare the roles of talin1 and
talin2 in tumorigenesis, talin1 and talin2 were depleted
with talin1 and talin2 shRNAs, respectively (Figure 4D).
MDA-MB-231 cells that express talin2 shRNAs were

RESULTS
To examine the role of talin2 in cell migration,
endogenous talin2 in MDA-MB-231 cells were depleted
by expressing talin2 shRNA (Figure 1A). Cell migration
was determined by time-lapse cell migration assays,
as described previously [27]. Depletion of talin2
significantly suppressed the migration of MDA-MB-231
cells (Figure 1B), by inhibiting directionality and velocity
(Figure 1C). Depletion of talin1 also inhibited cell
migration. However, talin1 affected velocity more than
directionality, whereas talin2 functioned oppositely (Data
not shown). To further examine the biological function
of talin2, we used CRISPR/Cas9 to knockout talin2 from
MDA-MB-231 cells. Ablation of talin2 was achieved
by infecting the cells with lentiviruses that express
Cas9 and talin2 gRNAs. Talin2 was completely ablated
in clones #1, #3 and #4, while was partially in clone #2
(Figure 2A). Thus, we chose clones #1, #3, and #4 for
further experiments. We examined the role of talin2 in cell
migration using transwell migration assays. Ablation of
talin2 significantly inhibited cell migration in the absence
of a growth factor chemoattractant, whereas had no
effect on EGF-induced cell migration (20 ng/ml EGF in
lower chambers; Supplementary Figure 1). These results
suggest that talin2 has distinct roles in cell migration under
different conditions.
Because FA dynamics is crucial for cell migration,
we examined the role of talin2 in FA dynamics. MDAMB-231 cells that stably express DsRed-paxillin were
infected with lentiviruses that express talin2 shRNA.
FA assembly and disassembly were determined as we
described previously [13, 27]. As shown in Figure 1D
and 1E, depletion of talin2 significantly inhibited both
FA assembly/disassembly rates in MDA-MB-231
cells, suggesting that talin2 regulates cell migration by
modulating FA dynamics.
To ascertain the role of talin2 in breast cancer cell
invasion, the invasion of talin2 knockout (KO) cells was
measured by examining the functional capacities of the
cells penetrating through transwell filters coated with
0.35 mg/ml Matrigel, using cells infected with empty
LentiCrispr vector as a control. Ablation of endogenous
talin2 significantly inhibited the basal (without growth
factors) as well as HGF-stimulated invasion of MDAMB-231 cells (Figure 2B, 2C). Depletion of talin2 by using
shRNAs also inhibited the invasion of MDA-MB-468 and
MDA-MB-435S cells (Supplementary Figure 2).
Previously, we demonstrated that substitution of
S339 with Cys caused significant reduction in the binding
of the talin2 head domain to β-integrin tails [25]. We
examined whether the mutation also inhibits the binding
www.impactjournals.com/oncotarget
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injected into female NCRNU mice by subcutaneous
injection, using cells expressing talin1 shRNA and cells
transfected with empty pLKO.1 vector as controls. Tumor
volumes were measured at 3 day intervals. As shown
in Figure 4E, tumor volumes from mice injected with
the cells expressing talin2 shRNA were significantly
smaller than those injected with the cells transfected
with empty vector, and were similar to those injected
with the cells expressing talin1 shRNA. At 30 days
after injection, mice were euthanized, and tumors were
removed, photographed and weighted. Either talin1 or
talin2 knockdown (KD) significantly inhibited tumor

growth (Figure 4F, 4G). Depletion of talin1 or talin2 also
suppressed cell proliferation in vitro (Figure 4H). These
data suggest that, like talin1, talin2 is also indispensable
for breast cancer cell tumorigenesis.
To determine whether a strong talin2-β-integrin
interaction is essential for tumorigenesis, talin2-null
MDA-MB-231 cells that re-express EGFP-talin2WT
or –talin2S339L were injected into female NCRNU mice
(Taconic) by subcutaneous injection, using talin2 null
cells as a control. Surprisingly, re-expression of talin2WT
in talin2-null cells completely abolished tumor growth,
whereas re-expression of talin2S339L, an integrin-binding

Figure 1: Talin2 is essential for cell migration and FA dynamics in MDA-MB-231 cells. (A) MDA-MB-231 cells were

infected with lentiviruses that express talin2 shRNAs or empty pLKO.1 vector (shRNA control). (B) Migration tracks of 10 MDA-MB-231
cells that stably express talin2 shRNAs or empty pLKO.1 vector. (C) Statistic results of velocity, total path length, net distance, and
directionality of the cells that stably express shRNA control or talin2 shRNA. The data are expressed as mean + S.E.M. of more than 50
cells from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control cells. (D) MDA-MB-231 cells that stably
express mDsRed-paxillin were infected with lentiviruses that express talin2 shRNA or empty pLKO.1 vector. The cells were plated on
fibronectin and the dynamics of paxillin were analysed using time-lapse TIRF microscopy. Inserts show enlarged FAs. Scale bar, 20 μm.
(E) Quantification of the FA assembly and disassembly rate constants in MDA-MB-231 cells that express talin2 shRNAs or empty pLKO.1
vector. Quantifications are expressed as mean ± S.E.M. of 60 FAs from 12 cells.
www.impactjournals.com/oncotarget
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deficient mutant, partially inhibited tumor growth (Figure
5B–5D). This inhibition is probably caused by the high
levels of re-expressed talin2WT, which are three fold higher
than the endogenous talin2 (Figure 5A). These results
suggest that exogenous expression of high levels of talin2
can inhibit tumorigenesis more efficiently than talin2 KD
(or KO).
To know the role of talin2 in breast cancer cell
metastasis, MDA-MB-231 cells that express talin2
shRNA or a control shRNA were injected into the tail
vein of female NCRNU mice (Taconic), comparing to
cells expressing talin1 shRNA. After six weeks, mice
were euthanized and tumor nodules on the surface of the
lungs were examined microscopically. The lungs from
the mice injected with the cells expressing talin1 or talin2

shRNAs had significantly less tumor nodules than those
injected with the cells infected with the control shRNA
(Figure 6A). Also, hematoxylin and eosin staining showed
that the lung sections from the mice injected with cells
expressing the control shRNA demonstrated numerous
tumor nodules, whereas those from mice injected with
cells expressing talin1 or talin2 shRNAs had fewer or no
tumor nodules (Figure 6B). These results indicate that both
talin1 and talin2 are indispensable for the metastasis of
MDA-MB-231 cells.
To examine the possible association of talin2 with
breast cancer progression, human breast cancer tissue
array slides, including 17 cases of ductal carcinoma in situ
(DCIS), 32 cases of invasive ductal carcinoma (IDC) and
30 cases of tumor adjacent tissues, were stained for talin2.

Figure 2: Strong binding of talin2 to integrins is required for the invasion of MDA-MB-231 cells. (A) Endogenous talin1
and talin2 in CRISPR vector-transfected and talin2-KO MDA-MB-231 cells. (B) Ablation of talin2 inhibited the invasion of MDA-MB-231
cells. HGF (20 ng/ml) was added to lower chambers where indicated. (C) Quantification of Experiment “B”. Data are presented as mean
± SEM from three independent experiments. t-test, *P < 0.05, **P < 0.01, compared to CRISPR control. (D) Binding of full-length EGFPtalin2WT or –talin2S339C to β1A-integrin tails measured by GST pull-down assays. The EGFP fusion proteins of talin mutants were transiently
expressed in CHO-K1 cells. (E) Stable expression of EGFP-talin2WT and -talin2S339C in talin2-null MDA-MB-231 cells using CRISPR. (F)
Talin2-null MDA-MB-231 cells that express EGFP-talin2WT or –talin2S339C were examined for their Matrigel invasive capacities, using
CRISPR vector-infected cells and talin2-null cells as controls. (G) Quantification of Experiment “E”. Data are presented as mean ± SEM
from three independent experiments. t-test, *P < 0.05 and ***P < 0.001, compared to CRISPR control.
www.impactjournals.com/oncotarget
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Immunohistochemical staining was performed as we
described previously [29]. Talin2 staining was significantly
higher in DCIS and IDC tissues than the staining in the
adjacent tissues (P < 0.001), and talin2 staining was
also higher in IDC tissues than DCIS tissues (P < 0.001;
Figure 6C). These data suggest that talin2 expression
positively correlates with human breast cancer progression.

assays, and that ablation of talin2 suppressed cell migration
in transwell migration assays in the absence of a growth
factor as a chemoattractant (Figure 1, Supplementary
Figure 1). Although the time-lapse migration assays were
performed in the presence of EGF, there was no EGF
gradient in the assays. Thus, the common factor in these
two different assays is lack of EGF gradient, suggesting
that talin2 is indispensable for cell migration when there is
no signal cue for the directionality. In contrast, talin2 KO
had no significant effect on cell migration in the presence
of EGF in transwell assays, where the EGF gradient
determined the directionality of migration. This result is
consistent with previous findings that talin2 deleted mouse
embryo fibroblasts showed no obvious defects in the
velocity of migration [24]. These results suggest that talin2
regulates cell migration by governing the directionality.
The role of talin2 in determining the directionality
of cell migration could be attributed to its effect in traction

DISCUSSION
In breast cancer cells, talin2 mediates traction
force generation through its high affinity to β-integrins,
thus regulating cell migration, invasion, tumor growth
and metastasis. Talin2 is indispensable for tumor growth,
although exogenous expression of excessive talin2 can
inhibit tumor growth.
We found that depletion of talin2 inhibited the
directionality of cell migration in time-lapse migration

Figure 3: Strong binding of talin2 to β-integrin tails is required for traction force generation. (A) Effects of talin2 KO

on traction force generation in MDA-MB-231 cells. Scale bar, 30 μm. (B) Quantitative constrained traction force in talin2-ablated MDAMB-231 cells, using cells carrying CRISPR vector as a control. Data are presented as mean ± SEM of at least 20 cells from each group.
t-test, *P < 0.05 and **P < 0.01, compared to CRISPR control. (C) Re-expression of talin2WT in talin2-null MDA-MB-231 cells restored
their traction force generation, but that of talin2S339C did not. Talin2-null MDA-MB-231 cells that express EGFP-talin2WT or –talin2S339C
were cultured on polyacrylamide gel containing Red FluoSpheres for determining traction force, using CRISPR vector-infected cells and
talin2-null cells as controls. Scale bar, 30 μm. (D) Quantitative constrained traction force. Data are presented as mean ± SEM of at least 40
cells from each group. t-test, ***P < 0.001, compared to talin2 KO cells.
www.impactjournals.com/oncotarget
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force (Figure 3), which can regulate the directionality of
cell migration [30]. Traction force also regulates focal
adhesion dynamics [31–34], a key step in cell migration
[20]. This is supported by our findings that talin2 is
required for focal adhesion dynamics (Figure 1D, 1E).
Moreover, focal adhesions are implicated in determining

the directionality of cell migration [35, 36]. Thus, talin2
regulates the directionality of migration by modulating
traction force and focal adhesion generation.
We recently reported that talin2 is required for EGFstimulated invasion of U2 OS human osteosarcoma cells
[25]. We show here that ablation of talin2 also inhibited

Figure 4: Talin2 is indispensable for tumor growth in a xenograft model of human breast cancer. (A–C), Talin2 KO

suppressed breast cancer tumorigenesis. Talin2 KO MDA-MB-231 cells (1 × 106) were injected subcutaneously to female NCR-NU mice
(five to six weeks old), using CRISPR vector cells as a control. Tumor size was measured when indicated with calipers, and tumor volumes
were calculated and plotted (A). After 36 days, mice were euthanized. Tumors were removed, fixed and photographed (B). Tumor weights
were measured with a balance with 0.001 g readability (C). (D) MDA-MB-231 cells were infected with lentiviruses that express talin1 or
talin2 shRNAs, using empty pLKO.1 vector as a control. (E–G) Both talin1 and talin2 KD inhibited tumor growth. Talin1 or talin2 KD
MDA-MB-231 cells (1 × 106) were injected to female NCR-NU mice (five to six weeks old), using pLKO.1 vector cells as a control. Tumor
volumes were calculated and plotted (E). After 30 days, mice were euthanized. Tumors were removed, fixed and photographed (F). Tumor
weights were measured (G). (H) Growth curves of talin1 and talin2 KD cells, compared to pLKO.1 vector cells.
www.impactjournals.com/oncotarget
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the invasion of MDA-MB-231 cells and traction force
generation (Figures 2, 3). Furthermore, re-expression
of talin2WT in talin2-null MDA-MB-231 cells rescued
cell invasion and traction force generation, whereas reexpression of talin2S339C, a β-integrin-binding deficient
mutant, did not. These results indicate that a strong
interaction between talin2 and β-integrins is essential
for traction force generation and cell invasion. Because
traction force plays an important role in invadopodia [25],
a key cellular structure for invasion, we conclude that
talin2-mediated traction force regulates breast cancer cell
invasion.
Talin1 knockdown in MDA-MB-231 cells inhibited
their tumorigenesis (Figure 4). This is consistent with
a previous report in human hepatocellular carcinoma
cells [16]. Similar to talin1, talin2 is also indispensable
for tumorigenesis in MDA-MB-231 cells. Ablation of
talin2 in MDA-MB-231 cells by CRISPR inhibited their
tumorigenesis (Figure 4). Similar result was observed in
mice injected with talin2 knockdown MDA-MB-231 cells.
These results suggest that talin2 is essential for tumor
growth.
Surprisingly, re-expression of talin2WT in talin2-null
MDA-MB-231 cells did not rescue their tumorigenesis;
instead, it completely abolished tumor growth (Figure 5).

The inhibition of talin2 is probably associated with the
abnormal expression levels of the exogenous talin2,
which is much higher than the endogenous. The inhibition
is dependent of the interaction of talin2 with β-integrins,
because re-expression of talin2S339L, a β–integrin-binding
deficient mutant, only partially inhibited tumor growth.
Thus, raising talin2 expression could be a better strategy
to inhibit breast cancer cell tumorigenesis than depleting
it, and it is likely that an activator (but not an inhibitor) of
the talin2-β-integrin interaction should be developed for
cancer treatment.
Nevertheless, the inhibition of talin2 on
tumorigenesis seems to be inconsistent with our
findings that talin2 staining in DCIS and IDC tissues
was significantly higher than the staining in the
adjacent tissues (Figure 6). The reason could be that the
exogenously expressed talin2 is much higher than the
talin2 expression in DCIS and IDC. Because a gene has to
collaborate with many other genes in the gene regulatory
network to regulate breast cancer growth [37, 38], it is
likely that exogenous over-expression of talin2 alone will
disrupt the gene regulatory network. Thus, to exogenously
express talin2 or its mutants in breast cancer cells for
studying tumor growth, a weaker promoter (such as EF1α) should be selected.

Figure 5: Re-expression of talin2 in talin2-null MDA-MB-231 cells abolished their tumorigenesis. (A) Stable expression

of EGFP-talin2WT and -talin2S339L in talin2-null MDA-MB-231 cells using CRISPR. B-D, Talin2-KO MDA-MB-231 cells that re-express
EGFP-talin2WT or -talin2S339L were injected subcutaneously to female NCR-NU mice, using talin2-KO cells as a control. Tumor size was
measured when indicated, and tumor volumes were calculated and plotted (B). After 39 days, mice were euthanized. Tumors were removed,
and photographed (C). Tumor weights were measured (D).
www.impactjournals.com/oncotarget
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MATERIALS AND METHODS
Reagents
Anti-talin1 (clone 97H6) and anti-talin2 (clone
53.8) antibodies were from AbD Serotec. Anti-talin2
rabbit polyclonal antibody (PB9961) was from Boster
(Pleasanton, CA). Anti-tubulin (C-terminus) mouse
monoclonal antibody (TP1691) was from ECM
Biosciences (Versailles, KY). Anti-GAPDH goat
polyclonal antibody (A00191) was from Genescript
(Piscataway, NJ). pLKO1 lentivirus shRNAs that
respectively target talin1 and talin2 were from Sigma.
Talin1 shRNA clones are TRCN0000123105 (#1),
TRCN0000299020 (#2) and TRCN0000299022 (#3).
Talin2 shRNA clones are TRCN0000122990 (#1)
and TRCN0000122992 (#2). LentiCRISPRv2 and
pSpCas9(BB)-2A-Puro V2.0, which were generated by
Dr. Feng Zhang’s Laboratory [39], were from Addgene.
Alexa488-labeled gelatin and Red FluoSpheres were from
Life Technologies. Dylight 680 labeled goat anti-rabbit
IgG (H+L) and Dylight 800-labeled goat anti-mouse
IgG (H+L) were from Thermo Scientific. Fibronectin
were from Akron Biotech. Growth factor- reduced
Matrigel was from BD Bioscience. Pfu Ultra was from
Agilent Technologies. Cold Fusion Cloning Kit was
from System Biosciences (Palo Alto, CA). Anti-GFP
monoclonal antibody and Safectine RU50 transfection kit

were purchased from Syd Labs (Malden, MA). Standard
VECTASTAIN ABC kit and ImmPACT DAB substrate kit
were from Vector Laboratories, Inc. DNA primers were
synthesized by Sigma-Aldrich.

Plasmid construction
The full-length pEGFP-talin2WT, pEGFP-talin2S339C,
pAAVS1-EGFP-talin2WT and pAAVS1-EGFP-talin2S339C
were reported previously [25]. The full-length pEGFPtalin2S339L was created by digesting full-length pEGFPtalin2 with BsrG1/EcoRV and ligating the resulting larger
fragment with the smaller fragment from pEGFP-talin21S339L
. The full-length pAAVS1-EGFP-talin2S339L was
449
created by digesting full-length pAAVS1-EGFP-talin2WT
with BsrG1/EcoRV and ligating the resulting larger
fragment with the smaller fragment from pEGFP-talin21S339L
. All plasmids were sequenced by Eurofins MWG
449
Operon (Huntsville, AL).

Cell culture and transfection
CHO-K1 Chinese hamster ovary cells, MDAMB-231 human breast cancer cells, and 293T human
embryonic kidney cells were from the American Type
Culture Collection and were maintained in DMEM
medium (Corning Inc.) containing 10% fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (100 µg/

Figure 6: The roles of talin1 and talin2 in the metastasis of MDA-MB-231 cells. (A) MDA-MB-231 cells that express shRNA
control, talin1 shRNA or talin2 shRNA were injected into the tail veins of ICR-SCID mice. After six weeks, lungs were excised, and the
numbers of tumor nodules on the lung surface were examined under a dissection microscope and plotted. *P < 0.05. (B) Hematoxylin and
eosin staining (40×) of paraffin-embedded sections of lung specimens from nude mice implanted with MDA-MB-231 cells that express
shRNA control, talin1 shRNA or talin2 shRNA. (C) Talin2 staining of human ductal carcinoma in situ and invasive ductal carcinoma tissues
as well as tumor adjacent tissue.
www.impactjournals.com/oncotarget
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ml). CHO-K1 and 293T cells were transfected with
Safectine RU50 according to the manufacturer’s protocol.

on MatTek dishes (with a glass coverslip at the bottom)
that had been precoated with fibronectin (5 µg/ml). The
cells were cultured for three hours and TIRF images
were taken using the Nikon Eclipse Ti TIRF microscope
equipped with a 60×, 1.45 NA objective, CoolSNAP HQ2
CCD camera (Roper Scientific). The temperature, CO2
and humidity were maintained by using INU-TIZ-F1
microscope incubation system (Tokai Hit). Images were
recorded at 1-minute intervals for a 60-minute period. FA
assembly and disassembly rate constants were analyzed as
described previously [13, 27, 40].

shRNA knockdown
shRNA plasmids were co-transfected with
packaging plasmids (pMDLg/pRRE, pRSV-Rev, and
CMV-VSVG) into 293T cells using Safectine RU50
transfection reagent according to the manufacturer’s
protocol. The virus particles were applied to overnight
cultures of breast cancer cells for infection. Cells that
stably express shRNAs were obtained by selecting the
infected cells with 1 μg/ml puromycin for 10 days.

Cell invasion assays

Talin2 re-expression by CRISPR

Cell invasion was performed as described previously
[29, 40]. Briefly, 100 µl of Matrigel (1:30 dilution in
serum-free DMEM medium) was added to each Transwell
polycarbonate filter and incubated at 37°C for five
hours. Cells were trypsinized, washed (three times), and
resuspended in DMEM containing 1% FBS at a density
of 5 × 105 cells/ml. The cell suspensions (100 µl) were
seeded into the upper chambers, and 600 µl of DMEM
medium containing 1% FBS, 20 ng/ml HGF and 10 µg/ml
fibronectin were added to the lower chambers. The cells
were allowed to invade for 10 hours (or as indicated) in a
CO2 incubator, fixed, stained and quantitated as described
previously [40].

Talin2-null MDA-MB-231 cells were reported
previously [25]. To re-express of talin2 and talin2S339L in
talin2-null MDA-MB-231 cells, AAVS1 gRNA was cotransfected with pAAVS1-EGFP-talin2WT and -EGFPtalin2S339L into talin2 null cells. Transfected cells were
selected with neomycin. EGFP-positive clones were
isolated. The re-expression of EGFP-talin2WT and -EGFPtalin2S339L was examined by western blot.

Cell migration assays
Cells were treated with trypsin and resuspended
in DMEM medium containing 1% FBS and 10 ng/ml
EGF, plated at low densities on glass-bottomed dishes
(MatTek) coated with 5 µg/ml fibronectin and cultured
for three hours in a CO2 incubator. Cell motility was
measured with a Nikon Biostation IMQ. Cell migration
was tracked for six hours; images were recorded every 10
minutes. The movement of individual cell was analyzed
with NIS-Elements AR (Nikon) as described previously
[27, 29].
To perform Transwell migration assays, Transwell
polycarbonate filters were coated with fibronectin (20 µg/
ml) for one hour. Cells were trypsinized and washed 3
times with DMEM containing 1% FBS. The cells were
resuspended in DMEM containing 1% FBS at a density
of 5 × 105 cells/ml. The cell suspensions (100 µl) were
seeded into the upper chambers, and 600 µl of DMEM
medium containing 1% FBS, and 10 µg/ml fibronectin
(and 20 ng/ml EGF where indicated) were added to the
lower chambers. The cells were allowed to migrate for 3.5
hours (or as indicated) in a CO2 incubator, fixed, stained
and quantitated as described previously [40].

Traction force measurement
Traction force was measured as described previously
[23, 25]. Briefly, glass-bottom dishes were silanized using
silane, and activated using glutaraldehyde. Forty µL of
gel containing acrylamide (6%), bis-acrylamide (0.75%),
ammonium persulfate, TEMED, and FluoSpheres®
carboxylate-modified beads (diameter 0.2 μm, 1:85
dilution by volume) was added to the dishes and covered
by a coverslip. The coverslip was removed, and gels
were activated with sulfo-SANPAH under UVA exposure
and then conjugated with fibronectin (0.1 mg/ml). Cells
were plated on the gels and traction force was measured
as described previously [41], using an A1 confocal
microscope in Lexington VA Medical Center.

Tumor growth assays
Female NCR-NU mice (Taconic, six–seven weeks
old) were maintained and treated under pathogen-free
conditions. MDA-MB-231 cells (1 × 106 cells/mouse)
were injected subcutaneously to female NCR-NU mice.
The injected mice were maintained under standard humane
conditions. Tumor volume (V) was measured with calipers
periodically and calculated by using formula V = 0.5 ×
LW2 (L, Length; and W, width). Mice were euthanized
after 30–40 days. Tumors were removed, weighed and
photographed.

FA dynamics assays
MDA-MB-231 cells that stably express DsRedpaxillin [27] were infected with lentiviruses that express
shRNA control, talin1 or talin2 shRNA and then selected
with puromycin. The cells were trypsinized and plated
www.impactjournals.com/oncotarget
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Tumor metastasis assays

2. Scales TM, Parsons M. Spatial and temporal regulation
of integrin signalling during cell migration. Curr Opin
Cell Biol. 2011; 23:562–568. http://dx.doi.org/10.1016/j.
ceb.2011.05.008.

Tumor metastasis was performed as described
previously [27]. Briefly, female ICR-SCID mice
(Taconic) were maintained and treated under pathogenfree conditions. Talin1 or talin2 KD MDA-MB-231 cells
(1 × 106 cells/mouse) were injected into the tail vein of
mice (six–seven weeks old), using shRNA vector cells as
a control. After six weeks, mice were euthanized and lungs
were removed and photographed. Tumor nodules present
on the surface of lungs were examined under a dissection
microscope or detected in paraffin-embedded sections
stained with hematoxylin and eosin.

3. Missan DS, DiPersio M. Integrin Control of Tumor
Invasion. Crit Rev Eukaryot Gene Expr. 2012; 22:309–324.
https://doi.org/10.1615/CritRevEukarGeneExpr.v22.i4.50.
4. Mercurio AM, Rabinovitz I. Towards a mechanistic
understanding of tumor invasion—lessons from theα 6 β
4integrin. Semin Cancer Biol. 2001; 11:129–141. http://
dx.doi.org/10.1006/scbi.2000.0364.
5. Juliano R. Cooperation between soluble factors and
integrin-mediated cell anchorage in the control of cell
growth and differentiation. BioEssays. 1996; 18:911–917.
https://doi.org/10.1002/bies.950181110.

Immunohistochemical staining

6. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin
signaling and cell growth control. Curr Opin Cell Biol.
1998; 10:220–231.

Breast cancer tissue arrays, with stage, grade and
normal breast tissue, were purchased from US BioMax.
The slides with tissue arrays were deparaffinized with
Xylene, dehydrated through three alcohol changes, and
performed antigen retrieval in 0.1 M citrate buffer (pH
6.0). The slides were treated with hydrogen peroxide
and then blocked with goat serum. The slides were
incubated with an affinity purified anti-talin2 rabbit
polyclonal antibody and then VECTASTAIN ABC kit
(Vector Laboratories, Inc). The slides were visualized
by incubating with a DAB substrate kit from the same
company. The correlation between talin2 expression and
tumor progression was scored and statistically analyzed.

7. Hynes RO. Integrins: bidirectional, allosteric signaling
machines. Cell. 2002; 110:673–687. https://doi.org/10.1016/
S0092-8674(02)00971-6.
8. Rees DJ, Ades SE, Singer SJ, Hynes RO. Sequence and
domain structure of talin. Nature. 1990; 347:685–689.
https://doi.org/10.1038/347685a0.
9. Nuckolls GH, Turner CE, Burridge K. Functional-studies
of the domains of talin. J Cell Biol. 1990; 110:1635–1644.
https://doi.org/10.1083/jcb.110.5.1635.
10. Calderwood DA, Zent R, Grant R, Rees DJ, Hynes RO,
Ginsberg MH. The Talin Head Domain Binds to Integrin
β Subunit Cytoplasmic Tails and Regulates Integrin
Activation. J Biol Chem. 1999; 274:28071–28074. https://
doi.org/10.1074/jbc.274.40.28071.
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